Snowflake Inc.

Genentech, Inc.

Ibio Limited

Bing Li

Edward Ma

Mingli Rui

Srinath Shankar

Zihan Li

Haowei Yu

Andong Zhan

Brian C Cunningham

Istvan Cseri

Napoleone Ferrara

Mohan Srinivasan

James A Wells

Isaac Kunen

Sachdev Singh Sidhu

Christian Wiesmann

Menno Van Lookeren Campagne

Bruce A Keyt

Matthew Paul Greving

Francis Hung Nguyen

Phung Tu Gip

Abraham M De Vos

Matt Lundberg

Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases, and in certain aspects: disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor, bind to a different epitope than to which Daclizumab or Baciliximab bind, exhibit a higher affinity of binding to CD25 at a pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4, and/or exhibit a higher affinity of binding to CD25 at a pH of about 6.5.

CD25 antibodies

A shared database platform can interface with a cluster computing platform over a network through a database connector and one or more cluster connectors. The data transferred over the network can include telemetry metadata that can be distributed to execution nodes of the cluster computing platform for generation and transmission of cluster data to the shared database platform.

Cluster diagnostics data for distributed job execution

A shared database platform can interface with a cluster computing platform over a network through a connector. The data transferred over the network can include metadata result packages that can be distributed to worker nodes of the cluster computing platform, which receive the metadata objects and access the result data for further processing on a staging platform, such as a scalable storage platform.

Distributed metadata-based cluster computing

The subject technology receives first code in a first programming language, the first code including a reference to a first dataset. The subject technology converting the first code to: second code in a second programming language different than the first programming language, and at least one data query in a second format different than the first programming language. Further the subject technology sends the converted first code and the at least one data query to a data system for execution.

Providing code translation related to resilient distributed datasets in database systems

A shared database platform can interface with a cluster computing platform over a network through a connector. The data transferred over the network can include metadata result packages that can be distributed to worker nodes of the duster computing platform, which receive the metadata objects and access the result data for further processing on a staging platform, such as a scalable storage platform.

The present invention concerns affinity matured CRIg variants. In particular, the invention concerns CRIg variants having increased binding affinity to C3b and retaining selective binding to C3b over C3.

Affinity matured CRIg variants

The present invention provides VEGF variants having one or more amino acid mutations in the KDR and/or FLT-1 receptor binding domains in the native VEGF sequence and selective binding affinity for either the KDR receptor or the FLT-1 receptor. Methods of making the VEGF variants and methods of using the VEGF variants are also provided.

Vascular endothelial cell growth factor variants and uses thereof

The present invention involves the preparation of vascular endothelial growth factor (VEGF) variants which provide materials that are selective in respect to binding characteristics to the kinase domain region and the FMS-like tyrosine-kinase region, respectively KDR and FLT-1. The respective KDR and FLT-1 receptors are bound by corresponding domains within the VEGF compound domains. The variants hereof define those two binding regions and modify them so as to introduce changes that interrupt the binding to the respective domain. In this fashion the final biological characteristics of the VEGF molecule are selectively modified.

Variants of vascular endothelial cell growth factor

Growing community of inventors

Foster City, CA, United States of America

Bing Li